Search PubMed⌕ Search

Biomedical subjects

G M Fuller

Publications and source records attributed to G M Fuller.

At least 19 recordsLinked to original sources
PubMed1995

Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter.

Fibrinogen, a hepatically derived class II acute phase protein, is the product of three separate genes, (A alpha, B beta, and gamma). The fibrinogen genes are expressed constitutively; however, their transcription can be significantly up-regulated by interleukin-6 (IL-6) and glucocorticoid. Inspection of the promoter region of the fibrinogen gamma gene revealed three hexanucleotide clusters of CTGGGA that are recognized as class II IL-6 responsive elements. Functional analyses of these regions (designated here as site I, site II, and site III according to their position in the promoter) were performed using luciferase reporter constructs and show a hierarchy of IL-6 response in which site II was the preferred functional site, site I was the next important site, and site III was the site least responsive to IL-6. Gel mobility shift assays using 25-base pair oligonucleotide probes derived from these three regions with the CTGGGA positioned in the middle and nuclear extracts from IL-6-treated primary hepatocytes reveal the presence of IL-6-induced high molecular weight complexes appearing 5 min after cytokine treatment. Supershift assays using anti-Stat3 antibody indicate that Stat3 is part of the IL-6-induced complex formed on the three gamma chain probes. The binding of Stat3 to the IL-6 responsive elements of the gamma probes is significantly weaker than to an alpha 2-macroglobulin probe. These findings show for the first time that Stat3 is involved in associating with the IL-6 responsive elements of fibrinogen gamma chain, a class II acute phase gene other than alpha 2-macroglobulin.

Acute-Phase Proteins↗
PubMed1995

Interleukin-6 and ciliary neurotrophic factor trigger janus kinase activation and early gene response in rat hepatocytes.

Interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF) share a signal-transducing molecule called gp130. Previous studies showed that CNTF regulates fibrinogen gene expression in rat hepatocytes by competitive binding to the IL-6 receptor. This report explores the post ligand-binding events in the control of fibrinogen and early response gene production stimulated by IL-6 and CNTF in primary rat hepatocytes. Metabolic labeling, using [32P]orthophosphate or anti-phosphotyrosine antibody (Ab) blot experiments revealed that both IL-6 and CNTF induced tyrosine phosphorylation of gp130, and the Jak1 and Jak2 kinases in a dose- and time-dependent manner. Additional experiments revealed that only one of the early response genes, junb, but not c-myc or c-fos, was stimulated by the addition of either IL-6 or CNTF. These data suggest that activation of Jak kinases and stimulation of junb reflect a divergence of the IL-6/CNTF signaling pathway and further suggest that junb may participate in cytokine control of acute-phase protein production in the inflammatory response.

Acute-Phase Reaction↗
PubMed1995

Detection of a novel transcription factor for the A alpha fibrinogen gene in response to interleukin-6.

The three fibrinogen genes belong to the class II hepatic acute phase proteins that are regulated in part by members of the interleukin-6 (IL-6) family of cytokines and glucocorticoids. The common DNA sequence that characterizes this group of proteins is a hexanucleotide CTGGGA residing in the promoter regions of these genes. Investigations of IL-6 control of the A alpha fibrinogen gene by electrophoretic mobility shift assays using a 30-base pair DNA probe containing the CTGGGA element revealed that a novel protein is associated with this site during non-IL-6-stimulated conditions. Sensitive time-course studies of IL-6 stimulation using primary hepatocyte cultures, high resolution polyacrylamide gel electrophoresis, and site-directed mutagenesis show that upon IL-6 stimulation of hepatocytes, this DNA binding protein transiently leaves the CTGGGA site and binds 12 base pairs down-stream but then begins to re-associate with the original DNA site at 1 h and is completed by 2 h. A recently characterized and cloned IL-6-activated transcription factor, Stat-3, which has been reported to bind a CT-GGGAA site in the alpha-2 macroglobulin gene, another member of the class II acute phase proteins, does not bind to the CTGGGA sequence in the A alpha fibrinogen gene. These findings reveal the presence of a previously undefined IL-6-regulated event, which involves a new DNA binding protein and demonstrates for the first time additional details of the kinetics of IL-6 control of fibrinogen gene expression.

Animals↗
PubMed1995

Biosynthetic and glycosylation events of the IL-6 receptor beta-subunit, gp130.

It is now recognized that the beta-subunit of the interleukin-6 (IL-6) receptor, also known as gp130, is a common signal transducer shared by other cytokines, including ciliary neurotrophic factor, leukemia inhibitor factor, oncostatin M, and IL-11. In this study, the biosynthesis and glycosylation of hepatic gp130 were investigated using a specific polyclonal antibody to the 287 amino acid cytoplasmic domain of gp130. Immunoprecipitation and metabolic labeling experiments demonstrate, in addition to a mature surface expressed gp130, the presence of a major immature form of the molecule within the cell. The immature form can shift to become a functional gp130 only after being terminally glycosylated. The kinetics of gp130 maturation and surface expression were determined. When both forms of gp130 are deglycosylated the resulting core peptides migrate to identical positions in a denatured protein gel, indicating that the principal difference between the two forms resides in the extent of their glycosylation. IL-6 and other members of this cytokine family activate only the mature form, demonstrating its location at the membrane surface. Protein and mRNA turnover studies reveal gp130 to be a stable, slowly renewing population under nonstimulated conditions. These findings provide novel information on the intracellular events leading to the expression of this critically important signal transducing protein.

Amidohydrolases↗
PubMed1995

Interleukin-6 stimulates hepatic triglyceride secretion in rats.

Interleukin-6 (IL-6) not only regulates a variety of immune functions, but also is the most potent cytokine in inducing the hepatic acute phase proteins. We determined the effect of IL-6 on serum lipid levels and the mechanism of IL-6-induced hypertriglyceridemia in rats. Intravenous administration of IL-6 (0.1-10 micrograms/200 g BW) increased serum triglyceride levels in a dose-dependent manner. One hour after IL-6 administration, serum triglyceride levels were increased, with peak values at 2 h (2.2-fold increase). Serum cholesterol levels also increased, but the effect was delayed, first occurring at 4 h and peaking at 8 h (1.24-fold increase). IL-6 treatment increased hepatic triglyceride secretion without decreasing the clearance of triglyceride-rich lipoproteins, indicating that the hypertriglyceridemia was due to increased secretion by the liver. Furthermore, IL-6 stimulates lipolysis, and the increased delivery of FFA to the liver significantly contributed to the IL-6-induced hypertriglyceridemia. Neither alpha 1- nor beta-adrenergic receptor antagonists affected the hypertriglyceridemia induced by IL-6, whereas previous studies have shown that endotoxin-induced hypertriglyceridemia was blocked by alpha-adrenergic receptor antagonists. These results demonstrate that IL-6 induces hypertriglyceridemia by stimulating hepatic triglyceride secretion independent of endogenous catecholamines. Thus, changes in hepatic triglyceride metabolism are another acute phase response that can be induced by IL-6.

Animals↗
PubMed1994

Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes.

Recent evidence has shown that members of the Jak kinase family are activated after IL-6 binds to its receptor complex, leading to a tyrosine phosphorylation of gp130, the IL-6 signal-transducing subunit. The different members of the IL-6 cytokine subfamily induce distinct patterns of Jak-Tyk phosphorylation in different cell types. Using monospecific antibodies to gp130, Jak2 kinase, and phosphotyrosine, we investigated the kinetics of IL-6 stimulation of members of this pathway in primary hepatocytes. Our findings show that Jak 2 is maximally activated within 2 min of exposure to IL-6, followed by gp130 phosphorylation that reaches its peak in another 2 min then declines to basal level by 60 min. In vitro phosphorylation experiments show that activated Jak 2 is able to phosphorylate both native gp130 and a fusion peptide containing its cytoplasmic domain, demonstrating gp130 is a direct substrate of Jak 2 kinase. Experiments designed to explore the cell surface expression of gp130 show that > or = 2 h are required to get a second round of phosphorylation after the addition of more cytokines. This finding suggests that activated gp130 is internalized from the cell surface after IL-6 stimulation. Additional experiments using protein synthesis inhibitors reveal that new protein synthesis is required to get a second cycle of gp130 phosphorylation indicating gp130 must be synthesized de novo and inserted into the membrane. These findings provide strong evidence that down regulation of the IL-6 signal in hepatocytes involves the internalization and cytosol degradation of gp130.

Animals↗
PubMed1993

Ciliary neurotrophic factor regulates fibrinogen gene expression in hepatocytes by binding to the interleukin-6 receptor.

Treatment of primary rat hepatocytes with ciliary neurotrophic factor (CNTF) resulted in increased fibrinogen mRNA levels and protein expression in a time- and dose- dependent manner. The stimulation was similar to but not as potent as the response observed with interleukin-6 (IL-6). Equilibrium binding studies using radioiodinated CNTF revealed approximately 1,900 binding sites per cell with a binding affinity of 1.6-2.0 nM, indicating the presence of specific CNTF receptors on the hepatocyte surface. Binding of CNTF to the hepatocyte surface could be competed by IL-6. Additionally, IL-6 binding was also competed by CNTF, although not entirely. These findings suggest that the CNTF-induced stimulation of fibrinogen gene expression occurs, at least in part, by this cytokine's interaction with the IL-6 receptor.

Animals↗
PubMed1992

Dynamics of interleukin-6 internalization and degradation in rat hepatocytes.

We have investigated the dissociation, internalization, and degradation of 125I-interleukin-6 (125I-IL-6) by primary rat hepatocytes. Temperature shift experiments following saturation binding of 125I-IL-6 to cell surface receptors in hepatocytes showed a rapid loss of surface-bound 125I-IL-6 (t1/2 = 15 min), concomitant with a rapid rise in internalized radiolabeled ligand. After reaching a maximum by 30 min at 37 degrees C, the level of internalized 125I-IL-6 decreased with time and appeared in the culture media in a non-trichloroacetic acid-precipitable (degraded) state. The addition of the lysosomotropic agent chloroquine inhibited this receptor-mediated degradation of IL-6 without affecting ligand internalization. Polyacrylamide gel electrophoresis analysis of internalized 125I-IL-6 confirms these results. Additionally, we show that the IL-6.IL-6 receptor complex is stable, and dissociation of these two molecular species occurs at a pH below 5.0. In contrast to published results, data presented in this study clearly indicate that IL-6 is rapidly internalized and degraded within hepatocytes by a receptor-mediated mechanism.

Animals↗
PubMed1992

Identification of a human cDNA with high homology to yeast omnipotent suppressor 45.

Omnipotent suppression is a well-established phenomenon in yeast and bacteria in which nonsense mutations are misread. Wild-type (wt) suppressors are presumed to be involved in ensuring the fidelity of translation. We report a human homolog to wt yeast omnipotent suppressor 45 which shares 63% identity at the nucleotide level in the area of open reading frame (ORF) and 73% similarity at the amino acid (aa) level. The aa sequence of the human protein was deduced from a 2.3-kb cDNA (TB3-1) isolated from an adenocarcinoma T84 cell line cDNA library. The cDNA contains an ORF of 1284 bp which encodes a 47.8-kDa protein. Two transcripts for the clone were identified (2.6 and 4.0 kb) in a variety of human cell types. The strong structural similarity to yeast omnipotent suppressor 45, and its widespread expression suggest that this cDNA may play a role in the accurate recognition of nonsense codons in mammalian cells.

Amino Acid Sequence↗
PubMed1992

Chromosomal localization of the IL-6 receptor signal transducing subunit, gp130 (IL6ST).

Signal transduction in eukaryotic cells is a complex process mediated, normally, by the interaction of soluble extrinsic protein factors and their cognate receptors. One example of this phenomena is the inflammatory cytokine interleukin-6 and the IL-6 receptor. However, the IL-6 receptor, once its ligand is bound, associates with another membrane glycoprotein, gp130, to potentiate the cytokine response. To further understand the basis of this interaction, and its possible implications in cellular transforming events, the corresponding gene(s) must be studied. Here we find that the human gp130 gene product is homologous to two distinct chromosomal loci on chromosomes 5 and 17. Furthermore, the presence of two distinct gp130 gene sequences is restricted to primates and is not found in other vertebrates.

Antigens, CD↗
PubMed1992

Chromosomal localization of a human cDNA containing a DIDS binding domain and demonstrating high homology to yeast omnipotent suppressor 45.

We recently have identified a full-length cDNA (TB3-1) from a human adenocarcinoma cell line T84 cDNA library that encodes a 47.8-kDa protein. TB3-1 shares identity with the putative yeast translation termination factor omnipotent suppressor 45. Using human-mouse somatic cell panel analysis, a family of sequences with high homology to the TB3-1 cDNA clone were localized to human chromosomes 5, 6, 7, and X. Southern analysis of a panel of mammalian and chicken genomic DNA demonstrates that TB3-1 is well conserved in higher vertebrates.

4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid↗
PubMed1992

Molecular cloning and characterization of the rat liver IL-6 signal transducing molecule, gp130.

Interleukin-6 (IL-6) is a multifunctional cytokine that exerts its effects on different target cells by interacting with a specific receptor. This interaction leads to the association and activation of a second membrane glycoprotein, gp130, which is the IL-6 signal transducing molecule. The nucleotide sequence of gp130 from a human B-cell line has been reported. We report here the cloning and sequence analysis of the gp130 molecule derived from rat liver. Comparison of gp130 molecules from the different species and cell types reveals 78% overall amino acid homology and 94% identity in the growth factor signaling domain. Two gp130 mRNA species, a moderately abundant species of 7.5 kb and a lesser one of 9.0 kb, were present in rat hepatocytes. Ribonuclease protection analyses demonstrated the presence of gp130 mRNA in four different nontransformed cell types: hepatocytes, astrocytes, fibroblasts, and endothelial cells. The sequences between both gp130s in the different cell types are quite similar, supporting the prediction that the different responses initiated by IL-6 on different target cells are modulated by cell-specific proteins distal to the activated gp130 molecule.

Amino Acid Sequence↗
PubMed1992

Differential regulation of interleukin-6 receptor and gp130 gene expression in rat hepatocytes.

Interleukin-6 (IL-6) relays an important signal to hepatocytes during the early stages of an acute inflammatory response, causing an alteration in the expression of several major defense proteins. Additional regulation of this signal could occur either by altering the number of IL-6 receptors (IL-6-R) or of the signal transducing protein, gp130. We employed ribonuclease protection assays to measure the expression of IL-6-R and gp130 mRNA in primary rat hepatocytes in response to IL-6, interleukin-1, dexamethasone, and combinations thereof. Dexamethasone increases receptor mRNA levels 2.7-fold above controls but has no detectable effect on that of gp130. Such treatment increased surface expression of IL-6-R from 600 receptors per cell to greater than 6000, without a change in Kd (2.5-4.6 x 10(-10) M). In contrast to the stimulatory effect of the steroid signal, the inflammatory cytokines, individually and together, down-modulated both the mRNA and the cell surface expression of IL-6-R. These findings demonstrate for the first time that a sensitive control system exists between inflammatory mediators and IL-6-R.

Animals↗
PubMed1991

Isolation and characterization of biologically active murine interleukin-6 produced in Escherichia coli.

Interleukin-6 (IL-6) is a multi-functional cytokine produced and secreted by several different cell types, including those of the immune system. A cDNA coding for the mature murine IL-6 (mIL-6), which extends from amino acid (aa) 25 through 211, was cloned into a prokaryotic vector and then expressed in Escherichia coli. The recombinant mIL-6 (remIL-6) was isolated from bacterial inclusion bodies by solubilization in 4 M guanidine hydrochloride followed by gel-filtration chromatography. The protein was refolded to an active conformation by dialysis against 25 mM Na. acetate pH 5.5. A final step of purification and concentration on a cation exchange resin yielded pure and biologically active remIL-6. The purified preparation had the expected aa composition, as confirmed by aa analysis and pI of 7.0-7.1. The biological activity of the recombinant protein was measured in two systems; a proliferation assay employing 7TD1 cells, and a fibrinogen biosynthesis assay employing primary rat hepatocytes. Both assay systems demonstrated that the remIL-6 was active in the range of 10(8) units/mg, which is similar to that estimated for native cytokine. Antibodies raised in rabbits against remIL-6 neutralized the biological activity of both recombinant and native IL-6.

Animals↗
PubMed1991

Identification and characterization of a C-terminally extended form of recombinant murine IL-6.

Murine interleukin-6 (mIL-6) was expressed in Escherichia coli in the insoluble fraction of cell lysates. Approximately equal amounts of two polypeptide species, reactive with anti-IL-6 antibodies, were produced. The two forms of mIL-6 were isolated and found to have identical N-terminal sequences initiated by Met-Phe-Pro-Thr-Ser-Gln-. Peptide mapping after endoproteinase glu-C digestion led to isolation and characterization of the C-terminal peptides from each of the two forms and allowed the source of the heterogeneity to be identified as a C-terminal addition of three amino acids, Gln-Lys-Leu, to authentic mIL-6. Inspection of the nucleotide sequence of the plasmid containing the mIL-6 gene and expression of the plasmid in other strains suggested that the addition of three amino acids was caused by a readthrough of the termination codon arising from an unexpected suppressor mutation in the original host strain. Although the C-terminus of IL-6 is critical for the activity of this cytokine, the IL-6 variant with extended C-terminus was fully active in two separate bioassays. This suggests that the additional amino acids do not disrupt the structure or function of this important region of the molecule.

Amino Acid Sequence↗
PubMed1991

Transcription and translation are required for fibrinogen mRNA degradation in hepatocytes.

Fibrinogen synthesis increases significantly during the early stages of an inflammatory reaction. In this study, we analysed quantitatively the fate of each fibrinogen transcript in primary rat hepatocytes during and following stimulation with interleukin-6 (IL-6). Northern blot hybridization analysis demonstrated a coordinated increase in the levels of fibrinogen mRNAs within 30 min following addition of IL-6. The half-life for each fibrinogen mRNA species was determined to be 8 h, and the decline in the level of all three fibrinogen transcripts occurred in a tightly coordinated fashion. When inhibitors of transcription (actinomycin-D) or translation (cycloheximide) were added following a maximal induction of fibrinogen mRNA expression by IL-6, the decay of mRNA was significantly diminished. Furthermore, the addition of cycloheximide (CHX) to hepatocytes increased fibrinogen mRNA levels, but only if the cells had been stimulated with IL-6. These data suggest that lability of the fibrinogen mRNAs may be due, in part, to the presence of a specific short-lived protein(s) that enhances their degradation. Constant exposure to IL-6 was required for the continual increase in expression of the fibrinogen mRNAs. Taken together, these results provide evidence that the turnover of fibrinogen mRNAs is stringently coordinated, and involves specific regulatory molecules yet to be characterized.

Animals↗
PubMed1991

The putative role of fibrin fragments in the biosynthesis of fibrinogen by hepatoma cells.

The current study reinvestigated whether pure plasminolytic fragments D and E from fibrin directly increase fibrinogen synthesized by the hepatocyte. Fibrinogen protein levels and fibrinogen mRNA levels in an interleukin-6 (IL-6) responsive rat hepatoma cell line (FAZA) were measured quantitatively by [35S]-methionine pulse-chase experiments and Northern hybridizations, respectively. The results demonstrate that neither fragments D nor E, alone or in combination, in the presence or absence of dexamethasone, had any influence on the production of fibrinogen.

Animals↗